Effect of Antiviral Drug on Viral Load Patients Infected with Hepatitis C Virus Genotype 3
Article Sidebar
Main Article Content
Abstract
Background: Hepatitis C Virus (HCV) genotype 3 is recognized for its rapid progression towards liver fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma, particularly in regions with high prevalence rates like Pakistan. Despite advances in treatment, understanding the efficacy and outcomes of direct-acting antiviral (DAA) therapy in this specific genotype remains crucial for optimizing clinical management and public health strategies.
Objective: This study aims to evaluate the efficacy and safety of daclatasvir and sofosbuvir combination therapy in patients with HCV genotype 3 infection, focusing on sustained virologic response (SVR), viral load reduction, and treatment-related adverse events.
Methods: A single-group, pretest-posttest design was utilized, involving 130 participants diagnosed with HCV genotype 3. Patients received a 12-week regimen of daclatasvir (60mg daily) and sofosbuvir (400mg daily). The study conducted thorough pre-treatment and post-treatment assessments, including ELISA for HCV antibodies, PCR for viral load determination, and genotyping. Statistical analyses were performed using SPSS version 25, with significance set at p<0.05.
Results: Of the 130 participants, 93% achieved SVR at 12 weeks post-treatment. The pre-treatment viral load ranged from 78,200 to 120,900,000 IU/mL, significantly decreasing post-treatment across the cohort. Genotype analysis confirmed HCV genotype 3 in 85.71% of cases. Treatment was well-tolerated, with no serious adverse events reported.
Conclusion: The combination therapy of daclatasvir and sofosbuvir was highly effective and safe in treating patients with HCV genotype 3 infection, demonstrating a high rate of SVR and a significant reduction in viral load without severe adverse events. These findings support the use of this regimen as a viable treatment option for this challenging HCV genotype.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
El-Ghitany EM. Hepatitis C virus infection in Egypt: current situation and future perspective. J High Inst Public Health. 2019 Apr 1;49(1):1-9.
Mitchell JK, Lemon SM, McGivern DR. How do persistent infections with hepatitis C virus cause liver cancer? Curr Opin Virol. 2015 Oct 1;14:101-8.
Riaz S, Bashir MF, Haider S, Rahid N. Association of genotypes with viral load and biochemical markers in HCV-infected Sindhi patients. Braz J Microbiol. 2016 Oct;47:980-6.
Merli M, Rattotti S, Spina M, Re F, Motta M, Piazza F, Orsucci L, Ferreri AJ, Perbellini O, Dodero A, Vallisa D. Direct-acting antivirals as primary treatment for hepatitis C virus–associated indolent non-Hodgkin lymphomas: the BArT study of the fondazione italiana linfomi. J Clin Oncol. 2022 Dec 12;40(35):4060.
Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017 Mar 2;3(1):1-9.
Cornberg M, Manns MP. The curing regimens of HCV: A SWOT analysis. Antiviral Ther. 2022 May 2;27(2):13596535211072672.
Safrin S. Antiviral agents. Basic Clin Pharmacol. 2018;11:845-75.
Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019 Nov;18(11):827-44.
Younossi ZM, Stepanova M, Feld J, Zeuzem S, Jacobson I, Agarwal K, Hezode C, Nader F, Henry L, Hunt S. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016 Jul 1;65(1):33-9.
Bhatia HK, Singh H, Grewal N, Natt NK. Sofosbuvir: A novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother. 2014 Dec;5(4):278-84.
Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015 Nov 1;64(11):1824-33.
Umer M, Iqbal M. Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data. World J Gastroenterol. 2016 Jan 1;22(4):1684.
Waheed Y, Najmi MH, Aziz H, Waheed H, Imran M, Safi SZ. Prevalence of hepatitis C in people who inject drugs in the cities of Rawalpindi and Islamabad, Pakistan. Biomed Rep. 2017 Sep 1;7(3):263-6.
Wahid B, Waqar M, Rasool N, Rehman Z, Saeed J, Wasim M, Khan MA, Ali A, Rafique S, Idrees M. Recent trends in molecular epidemiology of Hepatitis C virus in Mardan, KPK Pakistan. Infect Genet Evol. 2018 Dec 1;66:66-71.
Siddique MS, Shoaib S, Saad A, Iqbal HJ, Durrani N. Rapid virological&End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C. Pak J Med Sci. 2017 Jul;33(4):813.
Chatterjee K, Kalita D, Deka S, Jha MK, Gupta R, Omar BJ, Gupta P. Influence of Hepatitis C virus genotype and other factors on the viral load. Indian Journal of Medical Microbiology. 2024 Mar 1;48:100560.
Hawsawi NM, Saber T, Salama HM, Fouad WS, Hagag HM, Alhuthali HM, Eed EM, Saber T, Ismail KA, Al Qurashi HH, Altowairqi S. Genotypes of Hepatitis C virus and efficacy of direct-acting antiviral drugs among chronic hepatitis C patients in a Tertiary Care Hospital. Tropical Medicine and Infectious Disease. 2023 Jan 30;8(2):92.
Sparvoli JM, Sparvoli AC, Pereira AA, Paula AL, Garcia L, Gonçalves CV. Effects of hepatitis C virus genotypes and viral load on glucose and lipid metabolism after sustained virological response with direct-acting antivirals. Revista da Associação Médica Brasileira. 2023 May 19;69:e20221163.
Sahin A, Akay O. Experience with direct-acting antivirals in genotype 1–5 infected chronic hepatitis C patients in Turkey. Annals of Saudi Medicine. 2023 Sep;43(5):308-14.
Fuentes A, Abu-Dayyeh I, de Salazar A, Khasharmeh R, Al-Shabatat F, Jebrin S, Chueca N, Hamdan FM, Albtoush Y, Al-Shaer OA, Rashid MM. Molecular characterization of patients with chronic hepatitis C virus infection in Jordan: implications on response to direct-acting antiviral therapy. International Journal of Infectious Diseases. 2023 Oct 1;135:63-6.